Laurus Labs
Laurus Labs Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
CDMO division expects continued robust growth in FY '26 and beyond, with a well-diversified pipeline of late-stage clinical programs. Laurus Labs expects continued growth in their CDMO business, with FY '26 anticipated to be better than FY '25, though exact revenue or margin guidance is not provided.
From Laurus Labs's Q3 FY25 earnings-call transcript · updated 26 Aug 2026.
Revenue & Sales Performance
- CDMO division expects continued robust growth in FY '26 and beyond, with a well-diversified pipeline of late-stage clinical programs.
- No specific quantification for FY '26 sales, but prospects in CDMO are very bright with anticipated substantial growth over FY '25.
- Formulation and API businesses expected to see significant medium-term growth, possibly starting FY '27, as the pipeline broadens.
- Bio division growth expected to be limited in FY '26 due to capacity debottlenecking but anticipated to see big growth from FY '27 onwards.
- Animal health and CropScience segments to experience significant growth next year.
- The GMP gene therapy viral vector manufacturing facility to start contributing commercially from FY '26.
2 more points from Laurus Labs's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Laurus Labs said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Laurus Labs opened a new R&D center last quarter, equal in size to the current R&D, to handle more molecules and early-stage programs. Further augmentation of scientific talent is planned for more clinical programs.
- Capex philosophy: Investment will continue if opportunities arise; no fixed reduction plan.
- Investing around INR120 crores in a CGT (cell and gene therapy) GMP facility expected in FY '26, catering to viral vectors and plasmid manufacture.
- Two large-scale bio capacity facilities under construction: one in Vizag (operational by end of 2026) and another in Mysore.
- A 400 KL fermentation capacity being created mainly for internal use, not for partners.
2 more points from Laurus Labs's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Laurus Labs said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The company has a robust pipeline with multiple ongoing projects in the CDMO division, including more than 70 projects featuring breakthrough designated molecules.
- CDMO division recorded its highest quarterly sales in the last 8 quarters, close to INR 400 crores, with a 33% growth over 9 months, indicating strong demand and order flow.
- Multiple commercial launch quantities and registration batches were supplied in Q3 and Q4 for several products, showcasing diversified and growing orderbook.
- The company continues to receive encouraging RFPs (Request for Proposals) and is signing early to mid-stage projects involving complex chemistry.
- Augmentation of R&D and scientific talent is being done to handle more clinical programs and pipelines.
2 more points from Laurus Labs's call on order book
Pro opens every point from 15K+ earnings calls
Laurus Labs — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹1.8K Cr, net profit ₹282 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Laurus Labs Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Laurus Labs and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Laurus Labs Q3 FY25 results?
CDMO division expects continued robust growth in FY '26 and beyond, with a well-diversified pipeline of late-stage clinical programs. Laurus Labs expects continued growth in their CDMO business, with FY '26 anticipated to be better than FY '25, though exact revenue or margin guidance is not provided.
What is Laurus Labs share price analysis?
Laurus Labs currently shows a neutral. The stock trades at a P/E of 89.0 with a market cap of ₹97,364 Cr. Investors should review the full earnings analysis for detailed insights.
Is Laurus Labs planning capital expenditure?
Laurus Labs opened a new R&D center last quarter, equal in size to the current R&D, to handle more molecules and early-stage programs.
Keep Laurus Labs on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.